Vaccine: for Moderna, the efficacy is also exceptional
A vaccinated person has a 94.5% lower risk of developing symptoms of Covid-19.
A few days after issuing an emergency use authorization for Pfizer / BioNTech’s vaccine, the United States Medicines Agency (FDA) is due to meet this Thursday afternoon to rule on the fate of Moderna Therapeutics’ vaccine. Both are messenger RNA vaccines, a new technology that has never been commercialized to date.
The verdict should certainly be favorable, if we are to believe the results of the phase 3 clinical trial, unveiled Tuesday by the American regulator. We learn that Moderna’s vaccine is 94.5% effective in the two months following the second injection, which is the same as that of Pfizer / BioNTech (95%). And that without any particular side effect. In other words, a vaccinated person has a 94.5% lower risk of developing symptoms of Covid-19. “It’s quite exceptional, very few vaccines have such effectiveness”, underlines the Pr Odile Launay, infectious disease specialist and director
This article is for subscribers only. You have 77% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
Already subscribed? Log in